LDL-C-lowering therapy: current and future therapeutic targets.

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Intensive low-density lipoprotein cholesterol (LDL-C) lowering significantly reduces cardiovascular disease (CVD) risk.
• Maximizing statin therapy offers limited additional LDL-C reduction and increases side effect incidence.
• Novel therapeutic strategies are needed to achieve greater LDL-C lowering.

Purpose of the Study:

• To review emerging and investigational LDL-C-lowering modalities beyond conventional statin therapy.
• To evaluate the efficacy and safety profiles of alternative lipid-lowering agents.
• To discuss the potential of novel compounds in managing cardiovascular risk.

Main Methods:

• Review of recent clinical trial data and preclinical findings.
• Analysis of pharmacological mechanisms of action for various LDL-C-lowering agents.
• Comparative assessment of efficacy and adverse event profiles.

Main Results:

• Acyl-coenzyme A: cholesterol O-acyltransferase (ACAT) inhibitors have not demonstrated clinical benefit.
• Microsomal triglyceride transfer protein and squalene synthase inhibitors show mixed results with concerning adverse event profiles.
• Intestinal cholesterol absorption inhibitors and antisense oligonucleotides targeting apolipoprotein B100 synthesis show promising LDL-C-lowering efficacy with favorable safety.
• Protein convertase subtilisin/kexin type 9 (PCSK9) modifying compounds are in early development.

Conclusions:

• Alternative LDL-C-lowering strategies are crucial for further reducing cardiovascular risk.
• Intestinal cholesterol absorption inhibitors and antisense oligonucleotides represent promising therapeutic avenues.
• PCSK9-targeted therapies warrant further investigation in preclinical and clinical settings.